Interim analysis of the multinational, post-authorisation safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma: Time to onset of adverse events

• R. Gutzmer,
• P. Mohr,
• K. Kähler,
• P.A. Ascierto,
• M. Scalvenzi,
• K. Peris,
• G.M. Pérez-Pastor,
• R. Fernández-de-Misa,
• R. Botella Estrada,
• R. Hunger,
• S. Martelli,
• R. Arntz,
• A. Hauschild

Affiliations

R. Gutzmer

Universitätsklinik für Dermatologie, Venerologie, Allergologie und Phlebologie, Johannes Wesling Klinikum Minden UK der Ruhr-Universität Bochum, Department of dermatology, Minden, Germany

P. Mohr

Elbe Klinikum, Buxtehude, Germany

K. Kähler

University of Kiel, Department of Dermatology, Kiel, Germany

P.A. Ascierto

National Tumour Institute “Fondazione G. Pascale'', Unit of Melanoma Cancer Immunotherapy and Innovative Therapy, Naples, Italy

M. Scalvenzi

University of Naples Federico II, Department of dermatology, Naples, Italy

K. Peris

Fondazione Policlinico Universitario A. Gemelli-IRCCS, UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Rome, Italy

G.M. Pérez-Pastor

Hospital General Universitario de Valencia, Servicio de Dermatologia, Valencia, Spain

R. Fernández-de-Misa

Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain

R. Botella Estrada

Hospital Universitario La Fe Dermatología, Valencia, Spain

R. Hunger

Inselspital Bern, Universitätsklinik für Dermatologie, Bern, Switzerland

S. Martelli

Sun Pharmaceutical Industries B.V., Hoofddorp, The Netherlands

R. Arntz

Sun Pharmaceutical Industries B.V., Hoofddorp, The Netherlands

A. Hauschild

University of Kiel, Department of Dermatology, Kiel, Germany